Abstract
Identification of CD8+ and CD4+ T-cell defined tumor antigens has opened the way for possible cancer immunotherapy. Peptide-based active immunization has begun mainly targeting melanoma. Surprisingly, some objective responses were obtained in the initial trials, leading to the accumulation of an explosive number of such antigens. Serological screening of cDNA expression libraries accelerated the identification of immunodominant antigens, resulting in the emergence of the concept of a “cancer-testis antigen.” On the other hand, an advance in basic immunology has been promptly adopted: dendritic cells, as potent professional antigen presenting cells have been preferentially used in combination with the antigen in clinical trials both in vivo and in vitro. Tetramer analysis provided a powerful tool to directly monitor antigen-specific T cells in vivo in these trials. Moreover, adoptive transfer of antigen-specific T cells has added a new perspective to recent cancer immunotherapy.
Keywords: t-cell defined tumor antigen, epitope or agretope-altered peptide, cytotoxic t lymphocytes (ctl), cancer-testis (ct) antigen, cytokine, cancer immunotherapy
Current Pharmaceutical Design
Title: Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Volume: 9 Issue: 14
Author(s): Hideyuki Ikeda
Affiliation:
Keywords: t-cell defined tumor antigen, epitope or agretope-altered peptide, cytotoxic t lymphocytes (ctl), cancer-testis (ct) antigen, cytokine, cancer immunotherapy
Abstract: Identification of CD8+ and CD4+ T-cell defined tumor antigens has opened the way for possible cancer immunotherapy. Peptide-based active immunization has begun mainly targeting melanoma. Surprisingly, some objective responses were obtained in the initial trials, leading to the accumulation of an explosive number of such antigens. Serological screening of cDNA expression libraries accelerated the identification of immunodominant antigens, resulting in the emergence of the concept of a “cancer-testis antigen.” On the other hand, an advance in basic immunology has been promptly adopted: dendritic cells, as potent professional antigen presenting cells have been preferentially used in combination with the antigen in clinical trials both in vivo and in vitro. Tetramer analysis provided a powerful tool to directly monitor antigen-specific T cells in vivo in these trials. Moreover, adoptive transfer of antigen-specific T cells has added a new perspective to recent cancer immunotherapy.
Export Options
About this article
Cite this article as:
Ikeda Hideyuki, Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens, Current Pharmaceutical Design 2003; 9 (14) . https://dx.doi.org/10.2174/1381612033454973
DOI https://dx.doi.org/10.2174/1381612033454973 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Applications of Molecular Imaging in Cancer Gene Therapy
Current Gene Therapy TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Metabolomics for Personalized Nutrition Research and Clinical Applications
Current Pharmacogenomics and Personalized Medicine Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine Molecular and Genetic Profiling of Prostate Cancer: Implications for Future Therapy
Current Cancer Therapy Reviews Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Bringing Light into the Diagnosis of Skin Disorders - Short Review on Laser Induced Fluorescence Spectroscopy and Optical Coherence Tomography in Dermatology
Current Medical Imaging The Human L1 Element: A Potential Biomarker in Cancer Prognosis, Current Status and Future Directions
Current Molecular Medicine Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?
Current Neuropharmacology Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer
Current Cancer Drug Targets Novel Drugs Targeting Microtubules: the Role of Epothilones
Current Pharmaceutical Design The Adrenergic System in Gastrointestinal Cancers
Current Cancer Therapy Reviews Introduction: P2 Receptors
Current Topics in Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Targeting Hormonal Signaling Pathways in Castration Resistant Prostate Cancer
Recent Patents on Anti-Cancer Drug Discovery The Potential Use of Hormone-Based Therapeutics for the Treatment of Alzheimers Disease
Current Alzheimer Research Mandatory Reporting of Coronary Artery Calcifications Incidentally Noted on Chest Multi-Detector Computed Tomography: A Multicentre Experience
Current Vascular Pharmacology Innate T-Cell Immunity in HIV Infections: The Role of Vg9Vd2 T Lymphocytes
Current Molecular Medicine